Disease overview

Alterations

121

Molecular (A)

100

Clinical (B–E)

Direct drugs

167

Via biomarker

Natural agents

Natural products

104

Merged ranked

242

With trial/literature evidence

Sources: Seeds, Open Targets, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous PASI90 remission essentially zero without treatment; natural fluctuation occurs but complete clearance rare; <5% achieve sustained spontaneous remission over 5 years

Best-intervention remission

IL-17/IL-23 biologics achieve PASI100 (complete skin clearance) in 40-87% depending on agent and timeframe; complete clearance is now a realistic treatment goal, not a rarity

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — most patients never reach biologic therapy despite clear eligibility; on-drug clearance rates are exceptional but drug-free remission after cessation is short (12-32 weeks median for PASI loss)

Primary barrier

access/practice

Barrier detail: Most moderate-severe psoriasis patients remain on topicals or older systemics (methotrexate, cyclosporine) for years before biologics are offered; prior authorisation barriers significant; psoriasis is associated with cardiovascular risk requiring systemic treatment beyond skin clearance

Last SoC change: 2020-2022 — IL-23 inhibitors (risankizumab 2019, guselkumab 2017) established complete clearance as the new standard goal; IL-17 inhibitors since 2015; prior biologics (anti-TNF, ustekinumab) since 2009; methotrexate first-line unchanged since 1960s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: EFO: EFO_1001494

Alterations

121 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
AHR aryl hydrocarbon receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Adverse Events	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C1orf141 chromosome 1 open reading frame 141	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CAMK2G calcium/calmodulin dependent protein kinase II gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CARD14 caspase recruitment domain family member 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCDC88B coiled-coil and HOOK domain protein 88B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD2 CD2 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKAL1 CDKAL1 threonylcarbamoyladenosine tRNA methylthiotransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4 cytochrome c oxidase associated subunit FA4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4L2 cytochrome c oxidase hypoxia associated subunit FA4L2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF2RB colony stimulating factor 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 30) as Compared to the VitaminD Treated Area (Control) at End of Treatment (Week 12).	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Patient Self-assessment of Severity of Psoriasis of the Blue Light Treated Area (Group 30) Compared to the VitaminD Treated (Control) Area at Week 12 (VAS Scale).	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change in Itch Numeric Rating Scale scores (I-NRS)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
DENND1B DENN domain containing 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DHFR dihydrofolate reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Determination of safety and tolerability of treatment with si-544	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Determination of the efficacy of si-544 treatment as assessed by a numeric rating scale (NRS)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
EBF1 EBF transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELMO1 engulfment and cell motility 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETS1 ETS proto-oncogene 1, transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAM8A1 family with sequence similarity 8 member A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Frequency and Severity of Adverse Events and Serious Adverse Events (By Participant, Lead-in Phase)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFIH1 interferon induced with helicase C domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNLR1 interferon lambda receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL12A interleukin 12A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL12B interleukin 12B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL13 interleukin 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL17A interleukin 17A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL17F interleukin 17F	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL17RA interleukin 17 receptor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1RAP interleukin 1 receptor accessory protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1RL2 interleukin 1 receptor like 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL21 interleukin 21	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL23A interleukin 23 subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL23R interleukin 23 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF1 interferon regulatory factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITGAL integrin subunit alpha L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITGB2 integrin subunit beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK3 Janus kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAZF1 JAZF zinc finger 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MED15 mediator complex subunit 15	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA11 NADH:ubiquinone oxidoreductase subunit A11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA13 NADH:ubiquinone oxidoreductase subunit A13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF1 NADH:ubiquinone oxidoreductase complex assembly factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF3 NADH:ubiquinone oxidoreductase complex assembly factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF4 NADH:ubiquinone oxidoreductase complex assembly factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB1 NADH:ubiquinone oxidoreductase subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB2 NADH:ubiquinone oxidoreductase subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB6 NADH:ubiquinone oxidoreductase subunit B6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB8 NADH:ubiquinone oxidoreductase subunit B8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC1 NADH:ubiquinone oxidoreductase subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS4 NADH:ubiquinone oxidoreductase subunit S4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV3 NADH:ubiquinone oxidoreductase subunit V3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFKBIA NFKB inhibitor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOS2 nitric oxide synthase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4A phosphodiesterase 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4B phosphodiesterase 4B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4C phosphodiesterase 4C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4D phosphodiesterase 4D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLAU plasminogen activator, urokinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLI DNA polymerase iota	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPIA peptidylprolyl isomerase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPP3CA protein phosphatase 3 catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRDM1 PR/SET domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRR5L proline rich 5 like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPN2 protein tyrosine phosphatase non-receptor type 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Percentage of Participants Who Experienced Psoriasis Relapse (Treating Drop-Outs as Relapse)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: AUClast of Betamethasone 17-propionate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: AUClast of Betamethasone Dipropionate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: AUClast of Calcipotriol	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: AUClast of MC1080.	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: Cmax of Betamethasone 17-propionate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: Cmax of Betamethasone Dipropionate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: Cmax of Calcipotriol	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Pharmacokinetic: Cmax of MC1080	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Presence of typical psoriatic nail disease	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Proportion of subjects (≥ 1 grade change) on IGA scale	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Psoriasis Area and Severity Index (PASI) Score	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Psoriasis Area and Severity Index (PASI) at Week 16	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
RARA retinoic acid receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RARB retinoic acid receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RARG retinoic acid receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
REL REL proto-oncogene, NF-kB subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RIGI RNA sensor RIG-I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RUNX3 RUNX family transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRA retinoid X receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRB retinoid X receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRG retinoid X receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SOCS1 suppressor of cytokine signaling 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SPATA2 spermatogenesis associated 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SPOCK1 SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAGAP T cell activation RhoGTPase activating protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNF tumor necrosis factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFAIP3 TNF alpha induced protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNIP1 TNFAIP3 interacting protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNRC18 trinucleotide repeat containing 18	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TRAF3IP2 TRAF3 interacting protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYK2 tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Time to Psoriasis Relapse (Treating Drop-Outs as Relapse)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
UMPS uridine monophosphate synthetase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZC3H12C zinc finger CCCH-type containing 12C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
METHOXSALEN	Small molecule	Approved	Strong	100	3 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ALEFACEPT Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs View evidence Published literature Clinical trial publication Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis (Journal of translational medicine, 2007) Clinical trial publication Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris (Proceedings of the National Academy of Sciences of the United States of America, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris (The Journal of dermatological treatment, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLIOQUINOL Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT04220554 — Improvement of Psoriasis Patients' Adherence to Topical Drugs (COMPLETED) NA CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GEFITINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HALOPERIDOL DECANOATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVOTHYROXINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LITHIUM CATION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT06475586 — Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus (COMPLETED) PHASE4 NCT07516821 — Efficacy of Topical Metformin in Psoriasis Vulgaris (NOT_YET_RECRUITING) NA NCT03629639 — Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism (UNKNOWN) PHASE4 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLCELLULOSE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICLOSAMIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NITAZOXANIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OMEPRAZOLE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PHENAZOPYRIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
RESVERATROL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ROMIPLOSTIM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SITAGLIPTIN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAPINAROF Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
THIABENDAZOLE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ZINC CHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALEFACEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BERGAPTEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BRIAKINUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CERTOLIZUMAB PEGOL	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COUMARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EBDAROKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENVUDEUCITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETAROTENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUMARIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GUMOKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IB-MECA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOTROKINRA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRX4310	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIRIKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MUFEMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NETAKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ONERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ONZIGOLIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEFCALCITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEFICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PICANKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PICLIDENOSON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCONKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SPERMIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VEHICLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VOCLOSPORIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VUNAKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XALIPRODEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZASOCITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ABACAVIR HYDROXYACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATOCALCITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELAPECTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELUMOSUDIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERTILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE VALERATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BFH-772	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLESELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-582949	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMX-010	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMINOIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIACEREIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
E-6201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETARACIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEZAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK2981278	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK2982772	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDREBORMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITRUVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITX-5061	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LESTAURTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNACALCIPOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
M-1095	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0873	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAMILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEIHULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORILOTIMOD POTASSIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORISMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PARATHYROID HORMONE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGCANTRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONESIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIBOFLAVIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROPSACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERLOPITANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOTRASTAURIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALAROZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPILAMIDE FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIMOLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TISOCALCITATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREGALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ULODESINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VB-201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIMIROGANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIXARELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPLIZUMAB Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AZD-0284	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986020	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BOTULINUM TOXIN TYPE A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CC-90006	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CJM-112	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CRISABOROLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CUDC-305	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DALAZATIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMAPRELIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONABOTULINUMTOXINA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06263276	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PLACULUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAFINGOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TGN-1412	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACITRETIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANTHRALIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZARIBINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE BUTYRATE PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIMEKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BRODALUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CALCIPOTRIENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOBETASOL PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
COAL TAR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESOXIMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINASTINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HALOBETASOL PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HALOMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDIRUBIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MAXACALCITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MERCURY, AMMONIATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
R-348	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SPESOLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACALCITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAPINAROF	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAZAROTENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THYMOQUINONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TICOLUBANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TILDRAKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VANADATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALEFACEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BERGAPTEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BRIAKINUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CERTOLIZUMAB PEGOL	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COUMARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EBDAROKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENVUDEUCITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETAROTENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUMARIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GUMOKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IB-MECA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOTROKINRA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRX4310	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIRIKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MUFEMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NETAKIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ONERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ONZIGOLIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEFCALCITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEFICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PICANKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PICLIDENOSON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCONKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SPERMIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VEHICLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VOCLOSPORIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VUNAKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XALIPRODEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZASOCITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ABACAVIR HYDROXYACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATOCALCITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELAPECTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELUMOSUDIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERTILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE VALERATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BFH-772	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLESELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-582949	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMX-010	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMINOIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIACEREIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
E-6201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETARACIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEZAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK2981278	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK2982772	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDREBORMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITRUVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITX-5061	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LESTAURTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNACALCIPOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
M-1095	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0873	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAMILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEIHULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORILOTIMOD POTASSIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORISMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PARATHYROID HORMONE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGCANTRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONESIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIBOFLAVIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROPSACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERLOPITANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOTRASTAURIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALAROZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPILAMIDE FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIMOLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TISOCALCITATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREGALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ULODESINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VB-201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIMIROGANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIXARELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-0284	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986020	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BOTULINUM TOXIN TYPE A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CC-90006	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CJM-112	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CRISABOROLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CUDC-305	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DALAZATIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMAPRELIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONABOTULINUMTOXINA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06263276	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PLACULUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAFINGOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TGN-1412	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACITRETIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANTHRALIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZARIBINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE BUTYRATE PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIMEKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BRODALUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CALCIPOTRIENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLOBETASOL PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
COAL TAR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESOXIMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINASTINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HALOBETASOL PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HALOMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDIRUBIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MAXACALCITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MERCURY, AMMONIATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOXSALEN	Small molecule	Preclinical	Emerging	15	3 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
R-348	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SPESOLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACALCITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAPINAROF	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAZAROTENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THYMOQUINONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TICOLUBANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TILDRAKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VANADATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ALEFACEPT Repurposing via CD2	Small molecule	Approved	Strong	95	2 Trial pubs View evidence Published literature Clinical trial publication Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis (Journal of translational medicine, 2007) Clinical trial publication Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris (Proceedings of the National Academy of Sciences of the United States of America, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
AMPHETAMINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BOSUTINIB Repurposing via CAMK2G	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CAFFEINE Repurposing via AHR	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris (The Journal of dermatological treatment, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLIOQUINOL Repurposing via AHR	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT04220554 — Improvement of Psoriasis Patients' Adherence to Topical Drugs (COMPLETED) NA CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GEFITINIB Repurposing via CAMK2G	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GENISTEIN Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HALOPERIDOL DECANOATE Repurposing via CAMK2G	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVOTHYROXINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LITHIUM CATION Repurposing via CAMK2G	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE Repurposing via COXFA4L2	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT06475586 — Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus (COMPLETED) PHASE4 NCT07516821 — Efficacy of Topical Metformin in Psoriasis Vulgaris (NOT_YET_RECRUITING) NA NCT03629639 — Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism (UNKNOWN) PHASE4 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via AHR	Small molecule	Approved	Strong	95	3 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
METHYLCELLULOSE Repurposing via AHR	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
METOPROLOL Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICLOSAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NICOTINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NITAZOXANIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing via CD2	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OFLOXACIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OMEPRAZOLE Repurposing via AHR	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PHENAZOPYRIDINE HYDROCHLORIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
RESVERATROL Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ROMIPLOSTIM Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SITAGLIPTIN Repurposing via CDKAL1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAPINAROF Repurposing via AHR	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
THIABENDAZOLE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TROGLITAZONE Repurposing via AHR	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ZINC CHLORIDE Repurposing via CD2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DARAPLADIB Repurposing via AHR	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via AHR	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
SIPLIZUMAB Repurposing via CD2	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via AHR	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

104 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign… Human Study Vitamin D improves the condition of patients with psoriasis.	Nutraceutical	Approved	Emerging	19	6 trials View evidence Registry trials NCT01339741 — Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency (UNKNOWN) NA NCT01105286 — A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis (COMPLETED) PHASE1 NCT00678756 — Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol (UNKNOWN) PHASE2 NCT02735187 — Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D. (COMPLETED) NA NCT03874975 — Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris (UNKNOWN) EARLY_PHASE1 NCT02125279 — Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Human Study A B12 cream containing avocado oil has potential for the treatment of p… Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign…	Nutraceutical	Approved	Emerging	10	6 trials View evidence Registry trials NCT01339741 — Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency (UNKNOWN) NA NCT01105286 — A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis (COMPLETED) PHASE1 NCT00678756 — Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol (UNKNOWN) PHASE2 NCT02735187 — Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D. (COMPLETED) NA NCT03874975 — Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris (UNKNOWN) EARLY_PHASE1 NCT02125279 — Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Human Study EPA and DHA may have a therapeutic effect in patients with psoriasis an… Human Study Omega 3 fatty acids may have therapeutic value in treating Guttate psor…	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin B12 Natural product Human Study A B12 cream containing avocado oil has potential for the treatment of p… Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign…	Nutraceutical	Preclinical	Emerging	10	3 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin E Natural product Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study A B12 cream containing avocado oil has potential for the treatment of p… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign…	Nutraceutical	Phase III	Emerging	10	1 trials View evidence Registry trials NCT05906498 — Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Clinical trial publication Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Abl… Clinical trial publication Oral curcumin in the treatment of moderate to severe psoriasis vulgaris… Human Study Curcumin suppresses of phosphorylase kinase activity which is correlate…	Food compound	Phase II	Emerging	7	1 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT00235625 — Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris (COMPLETED) PHASE2 Published literature Clinical trial publication Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris (BioMed research international, 2015) Clinical trial publication Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial (Journal of the American Academy of Dermatology, 2008) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Black Seed Oil Natural product Animal Study, In Vitro Study Thymoquinone-loaded essential oil-based emulgel as an armament for anti… Animal Study An ethanolic extract of Nigella sativa seeds exhibits antipsoriatic act… Animal Study, In Vitro Study Novel nanoemulsion gel containing triple natural bio-actives combinatio…	Botanical	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Selenium Natural product Meta Analysis, Review Selenium levels were associated with several skin diseases and the dise… Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Human: Case Report Fecal microbiota transplantation as a novel therapy for severe psoriasi… Animal Study, In Vitro Study Dietary compounds as potential modulators of microRNA expression in pso… Animal Study, In Vitro Study Novel nanoemulsion gel containing triple natural bio-actives combinatio…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Coenzyme Q10 Natural product Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign… Animal Study, In Vitro Study Dietary compounds as potential modulators of microRNA expression in pso…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Sulforaphane Natural product Animal Study Sulforaphane ameliorates the severity of psoriasis and systemic lupus e…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Andrographis Natural product Animal Study The potential anti-psoriatic effects of andrographolide.	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Saffron Natural product Human Study An Edgar Cayce fashioned diet may prove effective in the treatment of p…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product Human In Vitro Berberine may serve as a potential therapeutic option for patients with…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Niacin Natural product Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign… Human Study Vitamin D improves the condition of patients with psoriasis.	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Moringa Natural product Animal Study, In Vitro Study Constituents of Moringa oleifera seeds regulate expression of Th17-rele…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Licorice Natural product Animal Study Isoliquiritigenin might serve as a potential candidate for treatment of…	Botanical	Preclinical	Emerging	2	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Cannabidiol Natural product Cannabidiol exerts multitarget immunomodulatory effects on PBMCs from i… Phytocannabinoids in the Pharmacotherapy of Psoriasis Cannabidiol Decreases Metalloproteinase Activity and Normalizes Angioge…	Food compound	Preclinical	Emerging	2	5 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Kaempferol Natural product Animal Study, In Vitro Study Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
8z-3,4',5-trimethoxystilbene Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Transtorine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-methylcholanthrene Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Beta-Naphthoflavone Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ruboxistaurin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Midostaurin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lestaurtinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ruxolitinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Prol…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alvocidib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Gilteritinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Crenolanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Momelotinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Asp-3026 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(Z)-octadec-11-enoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study Cholesterol-lowering drugs may contribute to skin disorders. Animal Study 5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatiti… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(9Z,12Z)-octadeca-9,12-dienoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study Cholesterol-lowering drugs may contribute to skin disorders. Animal Study 5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatiti… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
undecanoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study Cholesterol-lowering drugs may contribute to skin disorders. Animal Study 5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatiti… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
caprylic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product Human Study Cholesterol-lowering drugs may contribute to skin disorders. Animal Study 5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatiti… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-methylbutyric acid [(2S,3R,4R)-2-(4-hydroxy-3-methoxy-phenyl)-4-vanillyl-tetrahydrofuran-3-yl]methyl ester Natural product Human Study Cholesterol-lowering drugs may contribute to skin disorders. Animal Study 5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatiti… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Trimethoprim Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Methotrexate Natural product Animal Study Electroacupuncture and methotrexate cooperate to ameliorate psoriasifor…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pemetrexed Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Trimetrexate Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Aminopterin Natural product Methotrexate: from its introduction to non-oncologic therapeutics to an… An unusual side effect of aminopterin in the treatment of psoriasis vul… [Treatment of psoriasis vulgaris with aminopterin]	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pyrimethamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Flavonoids Natural product Animal Study Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-i… Animal Study Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation. Animal Study Metabolic profiling for unveiling mechanisms of kushenol F against imiq…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Indigo Naturalis Natural product Human Study Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in tr… Human Study Indigo naturalis (Strobilanthes) is a safe and effective treatment for… Human Study Indigo naturalis (Strobilanthes) is a safe and effective treatment for…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Shikonin Natural product Animal Study The combination of deucravacitinib and shikonin is a promising clinical…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginsenosides Natural product Animal Study A natural compound mixture ameliorates psoriasis-like skin lesions. Animal Study Ginsenoside compound K reduces psoriasis-related inflammation. Animal Study Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Peony Natural product Meta Analysis, Review Add-on effects of total glucosides of paeony on conventional therapies… Meta Analysis, Review Total glycosides of paeony can be used to treat psoriasis with reduced… Animal Study Effect of total glucosides of paeony on imiquimod-induced psoriatic ski…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sophora Flavescens Natural product Human Study Efficacy of oxymatrine for treatment and relapse suppression of severe… Human Study Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis… Animal Study Metabolic profiling for unveiling mechanisms of kushenol F against imiq…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sea Buckthorn Natural product Human Study Sea buckthorn extract in the treatment of psoriasis. Animal Study, In Vitro Study The present data suggest that Sea buckthorn oil can be used as an anti-…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Glycyrrhizin Natural product Meta Analysis, Review Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris. Animal Study Glycyrrhizin improves the pathogenesis of psoriasis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Aloe Vera Natural product Human Study Aloe gel is a safe and effective treatment for psoriasis. Animal Study, In Vitro Study Acemannan was effective in rejuvenating the affected skin.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Punicalagin Natural product Animal Study Oral administration of punicalagin attenuates imiquimod-induced psorias…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cannabinoids Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Babchi Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gallic Acid Natural product Human Study, In Vitro Study Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-1… Animal Study Gallic acid alleviates psoriasis keratinization and inflammation by reg…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Homeopathic Medicine: All Natural product Human Study A homeopathic form of M. aquifolium is effective and well tolerated in… Human Study Homeopathic treatment improves symptoms and quality of life in patients… Human: Case Report Use of Intercurrent remedy in the homoeopathic management of Psoriasis…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Honey Natural product Human Study A mixture of natural honey, beeswax and olive oil appears useful in the… Human Study Anti-inflammatory properties of raw honey and its clinical applications… Human Study Kanuka honey treatment was found to be both feasible and acceptable for…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Whey Natural product Human Study A whey protein concentrate has a therapeutic effect in mild to moderate…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hydrogen Water Natural product Human Study Hydrogen-water bathing therapy could fulfill the unmet need for these c… Animal Study A water-soluble extract from Actinidia arguta ameliorates psoriasis-lik… Animal Study Hydrogen-rich water ameliorates imiquimod-induced psoriasis-like skin l…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Genistein Natural product Human Study Impact of isoflavone genistein on psoriasis in in vivo and in vitro inv…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Pycnogenol (Pine Bark) Natural product Human Study These results indicate the efficacy of Pycnogenol supplementation in im…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rosmarinic Acid Natural product Human In Vitro Rosmarinic acid may be a potential candidate for the treatment of psori… Animal Study Rosmarinic acid protects mice from imiquimod induced psoriasis-like ski…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fisetin Natural product Human In Vitro These results suggest that fisetin has a great potential to be develope…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
18β-Glycyrrhetinic Acid Natural product Animal Study, In Vitro Study Anti-psoriasis effect of 18β-glycyrrhetinic acid. Animal Study Glycyrrhetinic acid ameliorates imiquimod-induced psoriasis-like skin l… Animal Study The protective effects of 18 β-glycyrrhetinic acid on imiquimod-induced…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Celastrol Natural product Animal Study Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cucurbitacin B Natural product Animal Study Cucurbitacin B alleviates skin lesions and inflammation in a psoriasis… Animal Study, In Vitro Study Cucurbitacin B may be a potential candidate for the treatment of psoria…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hesperidin Natural product Animal Study Hesperidin administration could have significant therapeutic value for… Animal Study Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis.	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Kaempferol Natural product Animal Study, In Vitro Study Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Betulinic Acid Natural product Animal Study Local and systemic effects of topical betulinic acid in a psoriasis-lik…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Magnolol Natural product Animal Study Magnolol may contribute to barrier function improvement on imiquimod-in…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Neem Natural product Animal Study Nimbolide has shown promising activity as an anti-psoriatic agent.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Paeonol Natural product Animal Study Paeonol may be a potent therapeutic treatment for psoriasis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lignans Natural product Animal Study Secoisolariciresinol diglucoside resolves systemic and skin inflammatio…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Salvia Miltiorrhiza Natural product Animal Study Tanshinol ameliorates imiquimod-induced psoriasis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Perilla Natural product Animal Study The essential oil derived from Perilla frutescens attenuates imiquimod-…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Vitamin a Natural product Human Study A B12 cream containing avocado oil has potential for the treatment of p… Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Human Study Supplementation with coenzyme Q10, vitamin E and selenium resut in sign…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Paeoniflorin Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Psoriasis (Nail / Palmoplantar)

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network